Recurrent Small Cell Lung Cancer Clinical Trial
Official title:
Phase II Trial of STI571 in Patients With Relapsed Small Cell Lung Cancer
Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have recurrent small cell lung cancer. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
PRIMARY OBJECTIVES:
I. Determine the response rate, time to progression, and overall survival of patients with
recurrent small cell lung cancer treated with imatinib mesylate.
II. Correlate the presence of c-Kit mutations in tumor tissue with treatment response in
patients treated with this drug.
III. Correlate individual patient variation in clinical (toxicity and/or activity),
pharmacologic (pharmacokinetic/pharmacodynamic parameters), and/or biologic (correlative
laboratory study results) responses to this drug with genetic differences in proteins
involved in drug response (transport, metabolism, and/or mechanism of action).
OUTLINE: This is a multicenter study. Patients are stratified according to length of prior
therapy (less than 3 months vs at least 3 months).
Patients receive oral imatinib mesylate twice daily for 28 days. Courses continue in the
absence of disease progression or unacceptable toxicity.
*Patients are followed every 3 months until disease progression and then every 6 months for
up to 3 years after registration.
NOTE: *Patients who develop CNS metastasis as the only site of disease progression receive
therapeutic whole-brain radiotherapy and then resume study therapy.
PROJECTED ACCRUAL: A total of 41 patients for stratum I will be accrued within 21 months and
50 patients for stratum II will be accrued within 25 months for this study.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01935336 -
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
|
Phase 2 | |
Completed |
NCT01931787 -
CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
|
Phase 1 | |
Terminated |
NCT01217411 -
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
|
Phase 1 | |
Terminated |
NCT04610658 -
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
|
Phase 1 | |
Completed |
NCT00773955 -
R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00528645 -
AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00028535 -
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03732846 -
Anlotinib in Treatment of Recurrent Small Cell Lung Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00828139 -
Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00086827 -
Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT01325753 -
Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body
|
N/A | |
Not yet recruiting |
NCT05162196 -
The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01155258 -
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
|
Phase 1 | |
Terminated |
NCT00088933 -
Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer
|
Phase 1 | |
Completed |
NCT00020202 -
FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01901653 -
Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00182689 -
Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01457469 -
Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer
|
Phase 1 | |
Completed |
NCT00098956 -
7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT01803269 -
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
|
Phase 2 |